Tubulis Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 45

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3.2B

Tubulis General Information

Description

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. The company's chemotherapeutic drugs are uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology, enabling doctors to treat cancer patients without any side effects related to chemotherapy.

Contact Information

Website
www.tubulis.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Am Klopferspitz 19 A
  • 82152 Planegg-Martinsried
  • Germany
+49 089
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Discovery Tools (Healthcare)
Parent Company
Gilead
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Am Klopferspitz 19 A
  • 82152 Planegg-Martinsried
  • Germany
+49 089

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tubulis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 21-May-2026 $3.2B Completed Clinical Trials - Phase 2
11. Later Stage VC (Series C) 15-Oct-2025 Completed Clinical Trials - Phase 2
10. Later Stage VC (Series B2) 14-Mar-2024 Completed Pre-Clinical Trials
9. Later Stage VC (Series B) 03-May-2022 Completed Pre-Clinical Trials
8. Accelerator/Incubator 01-Jan-2021 Completed Pre-Clinical Trials
7. Later Stage VC (Series A) 21-Jul-2020 Completed Pre-Clinical Trials
6. Later Stage VC (Series A) 01-Jan-2019 Cancelled Pre-Clinical Trials
5. Grant 19-Mar-2018 Completed Pre-Clinical Trials
4. Grant 01-Apr-2017 Completed Pre-Clinical Trials
3. Grant 01-Jan-2017 $526K Completed Pre-Clinical Trials
To view Tubulis’s complete valuation and funding history, request access »

Tubulis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. The company's chemotherapeuti
Drug Discovery
Planegg-Martinsried, Germany
45 As of 2026

Oxford, United Kingdom
 

Epalinges, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tubulis Competitors (3)

One of Tubulis’s 3 competitors is Oxford Biotherapeutics, a Private Equity-Backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Biotherapeutics Private Equity-Backed Oxford, United Kingdom
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
Glycotope Formerly VC-backed Berlin, Germany
You’re viewing 3 of 3 competitors. Get the full list »

Tubulis Patents

  • 41

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 31

    Pending

  • Expiring in next 12 mo

Tubulis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260174886-A1 Conjugates comprising a phosphorus(v) moiety and a protac Pending 26-Jun-2024
WO-2026003185-A1 Conjugates comprising a phosphorus(v) moiety and a protac Pending 26-Jun-2024
WO-2025248090-A1 Novel brd4 binders Pending 31-May-2024
AU-2024332412-A1 Methods of preparing phosphonamidate compounds Pending 01-Sep-2023
EP-4771024-A1 Methods of preparing phosphonamidate compounds Pending 01-Sep-2023 C07F9/4476
To view Tubulis’s complete patent history, request access »

Tubulis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tubulis Former Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andera Partners PE/Buyout Minority
Ascenta Capital Venture Capital Minority
Bayern Kapital Venture Capital Minority
BioMedPartners Venture Capital Minority
Blackstone PE/Buyout Minority
You’re viewing 5 of 26 investors. Get the full list »

Ready to get started?

Request a free trial

Tubulis FAQs

  • When was Tubulis founded?

    Tubulis was founded in 2012.

  • Where is Tubulis headquartered?

    Tubulis is headquartered in Planegg-Martinsried, Germany.

  • What is the size of Tubulis?

    Tubulis has 45 total employees.

  • What industry is Tubulis in?

    Tubulis’s primary industry is Drug Discovery.

  • Is Tubulis a private or public company?

    Tubulis is a Private company.

  • What is the current valuation of Tubulis?

    The current valuation of Tubulis is .

  • What is Tubulis’s current revenue?

    The current revenue for Tubulis is .

  • How much funding has Tubulis raised over time?

    Tubulis has raised $618M.

  • Who are Tubulis’s investors?

    Andera Partners, Ascenta Capital, Bayern Kapital, BioMedPartners, and Blackstone are 5 of 26 investors who have invested in Tubulis.

  • Who are Tubulis’s competitors?

    Oxford Biotherapeutics, ADC Therapeutics, and Glycotope are competitors of Tubulis.

  • When was Tubulis acquired?

    Tubulis was acquired on 21-May-2026.

  • Who acquired Tubulis?

    Tubulis was acquired by Gilead.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process